Page 134 - 2019_10 resto del Mondo_web

R. Bassan et al.
title and abstract screening. An additional four full papers were included that were not identified during the sys- tematic literature searches, giving a total of 1,903 records (Figure 1). Following screening of the title and abstract of each record, 278 records were included in the full text screen. Finally, 33 full papers and 21 congress abstracts were covered in the systematic review; these included 8,820 patients with B-ALL, 5,979 of whom had available MRD data. The study and patients’ characteristics, together with clinical outcomes, are summarized in Online Supplementary Tables S2–S7. In total, 32 records
(23 full texts and 9 congress abstracts) were eligible for the meta-analysis; of these, 23 records were included in the primary analysis set; the remaining papers were excluded because either the study populations over- lapped with another, more recent, publication, and there were no unique data for inclusion in the meta-analysis, or inconsistencies in data reporting meant that it was not possible to calculate hazard ratios. A list of studies iden- tified in the systematic review but not included in the meta-analysis, with reasons, is provided in Online Supplementary Table S8.
Figure 1. PRISMA flow diagram. aIncludes four full text articles that were not identified during the systematic literature searches. bProtocol amendment. Includes disease-free survival, leukemia-free survival and duration of complete response or progression-free survival. ALL: acute lymphoblastic leukemia; B cell ALL/B-ALL: B-cell acute lymphoblastic leukemia; HR: hazard ratio; MRD: minimal residual disease; MRD−: minimal residual disease-negative status; MRD+: minimal residual disease-positive status; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses; RFS: relapse-free survival; T cell ALL/T-ALL: T-cell acute lym- phoblastic leukemia.
2030
haematologica | 2019; 104(10)